HOME
OUR COMPANY
OUR HISTORY
OUR COMMITMENT TO SERIOUS DISEASE
OUR PATIENTS
OUR COMPANY GIVING
PRODUCTS
OUR PRODUCTS
IMMUNOLOGY
ONCOLOGY
NEPHROLOGY
OTHER SUPPORTED CONDITIONS
ACCESS TO MEDICINES
TRANSPARENCY
PHYSICIAN PAYMENTS
MEDICAL EDUCATION
CHARITABLE CONTRIBUTIONS
HEALTHCARE PROVIDERS
NEWS CENTER
MEDIA CONTACTS
News Center
MEDIA CONTACTS
Home
>
NEWS CENTER
PRESS RELEASES
05/16/2013
SIMPONI® (GOLIMUMAB) RECEIVES FDA APPROVAL FOR ULCERATIVE COLITIS
04/18/2013
Richard Petty Teams Up With Janssen Biotech to Launch Show Your Stripes for Prostate Cancer Awareness
04/08/2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
02/12/2013
Follow-up Data Show ZYTIGA
®
Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy
02/12/2013
Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
12/10/2012
U.S. FDA APPROVES EXPANDED ZYTIGA
®
INDICATION FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
12/06/2012
JANSSEN SUBMITS APPLICATIONS REQUESTING APPROVAL OF STELARA® IN U.S. AND EUROPE FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
11/12/2012
NEW PHASE 3 FINDINGS SHOW STELARA
®
SIGNIFICANTLY REDUCED SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS
11/12/2012
PHASE 3 DATA SHOW INTRAVENOUS GOLIMUMAB INHIBITED RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
11/08/2012
WHAT MEN SHOULD KNOW ABOUT PROSTATE CANCER – BUT DON’T
10/22/2012
NEW ONE-YEAR PHASE 3 STUDY RESULTS SHOW ANTI-TNF SIMPONI
®
MAINTAINED CLINICAL RESPONSE IN TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
10/17/2012
CROHN’S DISEASE PATIENTS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS SHOWED IMPROVEMENT IN DISEASE WITH STELARA
®
TREATMENT
10/01/2012
JANSSEN ANNOUNCES WORLDWIDE AGREEMENT TO DEVELOP AND COMMERCIALIZE JAK INHIBITOR FOR IMMUNOLOGICAL DISEASES
09/30/2012
NEW ZYTIGA
®
(ABIRATERONE ACETATE) DATA ON PAIN AND FUNCTION PRESENTED AT THE ESMO 2012 CONGRESS(EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY)
09/18/2012
JANSSEN SUBMITS APPLICATION TO FDA REQUESTING APPROVAL OF SIMPONI
®
INTRAVENOUS FORMULATION FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
08/30/2012
JANSSEN BIOTECH ANNOUNCES GLOBAL LICENSE AND DEVELOPMENT AGREEMENT FOR INVESTIGATIONAL ANTI-CANCER AGENT DARATUMUMAB
08/29/2012
U.S. FDA GRANTS PRIORITY REVIEW OF ZYTIGA
®
(ABIRATERONE ACETATE) SNDA FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER BEFORE CHEMOTHERAPY
07/16/2012
JANSSEN SUBMITS APPLICATIONS REQUESTING APPROVAL OF SIMPONI
®
IN U.S. AND EUROPE FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
06/25/2012
SEASON 10 AMERICAN IDOL FINALIST AND MUSICIAN CASEY ABRAMS RELEASES NEW SONG DEVOTED TO RAISING AWARENESS ABOUT INFLAMMATORY BOWEL DISEASE